Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by FibroBiologics, Inc.

< Previous 1 2 Next >
News headline image
FibroBiologics to Present at the DealFlow Discovery Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Payoff of Outstanding Debt
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at Bio-Europe 2025
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the 2025 ThinkEquity Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the BIO International Convention 2025
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.